CombiGene has, in collaboration with Associate Professor David Woldbye at University of Copenhagen and Professor Merab
Initial data from CombiGene’s preclinical proof-of-concept-study (the long-term study) show that CombiGene’s candidate drug, CG01, has
Our idea of “Ingeneious” is to keep you updated about the company’s journey and development and
The long-term study, part of CombiGene's epilepsy project, is a decisive preclinical proof-of-concept-study, the results of
On the 9th of November, ARM (Alliance for Regenerative Medicine) together with Catapult (a British organisation
Since work on the Q3 interim report has progressed more quickly than expected, the Board of
Our idea of “Ingeneious” is to keep you updated about the company’s journey and development and
Detta den första genterapiprodukten med godkännande för den amerikanska marknaden och därmed en historisk milstolpe för